## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 13.9% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-1.5% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($40.38)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Taking Stock of Omnicell (OMCL) After Titan XT Launch: What the New Platform Means for Valuation**
- Source: Simply Wall Street | 20251215T040933 | Somewhat-Bullish | Relevance: 100%
- Omnicell (OMCL) recently launched Titan XT, an automated dispensing platform integrated with its OmniSphere cloud, raising questions about its impact on growth and valuation. The stock has seen strong short-term gains, yet remains at a modest discount to analyst targets, potentially signaling a reevaluation of Omnicell's long-term prospects. While analysts project upside, the company's high P/E ratio suggests significant valuation risk if growth falters.

**2. Omnicell Shares Surge on Robust Earnings and Strategic Product Launch**
- Source: AD HOC NEWS | 20251213T070911 | Bullish | Relevance: 100%
- Omnicell's shares surged due to robust third-quarter 2025 earnings which exceeded market expectations, and the strategic launch of its new "Titan XT" medication dispensing system. Analysts have reinforced a positive outlook with raised price targets, despite the company acknowledging a need to improve long-term profitability. The transition towards recurring SaaS revenue is expected to drive better margins.

**3. Omnicell (OMCL) Stock Today: Titan XT Launch, New $50 Price Target and What It Means for 2025 Investors**
- Source: ts2.tech | 20251210T130911 | Bullish | Relevance: 100%
- Omnicell (OMCL) is gaining attention due to its new Titan XT product launch, raised Q3 2025 guidance, improving technical momentum, and analyst upgrades, including a new $50 price target from Benchmark. The company's stock has rebounded, reflecting a shift towards a more connected devices and SaaS platform model, though profitability still requires improvement. Investors are watching whether Omnicell can maintain revenue growth and improve margins to justify the recent rally.

**4. Omnicell, Inc. $OMCL Stock Holdings Raised by Liontrust Investment Partners LLP**
- Source: MarketBeat | 20251214T120933 | Neutral | Relevance: 100%
- Liontrust Investment Partners LLP significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, now holding 318,284 shares valued at $9.36 million. The stock, which has high institutional ownership (97.70%), is currently rated as a "Hold" with an average price target of $43.00, though analysts' views vary. Omnicell currently trades around $43.86 with a market cap of $1.97 billion.

**5. Federated Hermes Inc. Reduces Holdings in Omnicell, Inc. $OMCL**
- Source: MarketBeat | 20251211T120902 | Neutral | Relevance: 100%
- Federated Hermes Inc. significantly reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 20.3% in the second quarter, selling over 150,000 shares. Despite this, other institutions like GAMMA Investing LLC and AlphaQuest LLC increased their holdings, and insider EVP Corey J. Manley also sold shares. Omnicell, with a market cap of $1.97 billion and a high P/E ratio of 102.26, has a mixed analyst outlook with an average "Hold" rating, though Benchmark recently upgraded its target to $50 with a "Buy" rating.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Benchmark | $50 | $45 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Benchmark | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($1.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 23.8x stretched relative to 8% growth. Analyst sentiment positive (1 raises, avg +11%). Insider selling cluster ($1.2M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.0B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.69 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 23.8 |
| Current P/E | 25.6 |
| YoY Growth | 7.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 15.4% to 13.9% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (13.9% > 10.0%), caution on chasing. MRS_5 at 1.9% confirms short-term momentum alignment. AM_20 at 14.2% shows strong absolute momentum above own 20MA. Outperforming sector by 14.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.53), confirming momentum. RSI overbought at 75, risk of mean reversion. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 13.88% (CS: 97) | Strong |
| RSI_14 | 75.4 | Overbought |
| MACD Histogram | 0.53 | Bullish |
| vs SMA20 | 1.142x | Above |
| vs SMA50 | 1.265x | Above |
| vs SMA200 | 1.373x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $43.86
- **Stop Loss:** $40.38 (7.9% risk)
- **Target:** $47.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 287
- **Position Value:** $12,587.82
- **Portfolio %:** 12.59%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*